A Phase 2a Randomized, Parallel Group, Dose-Ranging Study of Molindone in Children with Attention-Deficit/Hyperactivity Disorder and Persistent, Serious Conduct Problems was written by Stocks, Jennifer Dugan;Taneja, Baldeo K.;Baroldi, Paolo;Findling, Robert L.. And the article was included in Journal of Child and Adolescent Psychopharmacology in 2012.Recommanded Product: 15622-65-8 This article mentions the following:
Objective: To evaluate safety and tolerability of four doses of immediate-release molindone hydrochloride in children with attention-deficit/hyperactivity disorder (ADHD) and serious conduct problems. Methods: This open-label, parallel-group, dose-ranging, multicenter trial randomized children, aged 6-12 years, with ADHD and persistent, serious conduct problems to receive oral molindone thrice daily for 9-12 wk in four treatment groups: Group 1-10 mg (5 mg if weight <30 kg), group 2-20 mg (10 mg if <30 kg), group 3-30 mg (15 mg if <30 kg), and group 4-40 mg (20 mg if <30 kg). The primary outcome measure was to evaluate safety and tolerability of molindone in children with ADHD and serious conduct problems. Secondary outcome measures included change in Nisonger Child Behavior Rating Form-Typical Intelligence Quotient (NCBRF-TIQ) Conduct Problem subscale scores, change in Clin. Global Impressions-Severity (CGI-S) and -Improvement (CGI-I) subscale scores from baseline to end point, and Swanson, Nolan, and Pelham rating scale-revised (SNAP-IV) ADHD-related subscale scores.Results: The study randomized 78 children; 55 completed the study. Treatment with molindone was generally well tolerated, with no clin. meaningful changes in laboratory or phys. examination findings. The most common treatment-related adverse events (AEs) included somnolence (n=9), weight increase (n=8), akathisia (n=4), sedation (n=4), and abdominal pain (n=4). Mean weight increased by 0.54 kg, and mean body mass index by 0.24 kg/m2. The incidence of AEs and treatment-related AEs increased with increasing dose. NCBRF-TIQ subscale scores improved in all four treatment groups, with 34%, 34%, 32%, and 55% decreases from baseline in groups 1, 2, 3, and 4, resp. CGI-S and SNAP-IV scores improved over time in all treatment groups, and CGI-I scores improved to the greatest degree in group 4. Conclusions: Molindone at doses of 5-20 mg/day (children weighing <30 kg) and 20-40 mg (鈮?0 kg) was well tolerated, and preliminary efficacy results suggest that molindone produces dose-related behavioral improvements over 9-12 wk. Addnl. double-blind, placebo-controlled trials are needed to further investigate molindone in this pediatric population.Clin. trials.gov Identifier: NCT00626236. In the experiment, the researchers used many compounds, for example, 3-Ethyl-2-methyl-5-(morpholinomethyl)-6,7-dihydro-1H-indol-4(5H)-one hydrochloride (cas: 15622-65-8Recommanded Product: 15622-65-8).
3-Ethyl-2-methyl-5-(morpholinomethyl)-6,7-dihydro-1H-indol-4(5H)-one hydrochloride (cas: 15622-65-8) belongs to indole derivatives. The indole subunit is an almost ubiquitous component of biologically active natural products, and its study has been the focus of research for decades.Indole was synthesized in moderate yield via an o-naphthoquinone catalyzed tandem cross-coupling of substituted aniline and benzylamine under aerobic oxidation conditions.Recommanded Product: 15622-65-8
Referemce:
Indole alkaloid derivatives as building blocks of natural products from聽Bacillus thuringiensis聽and聽Bacillus velezensis聽and their antibacterial and antifungal activity study,
Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles